Convalescent plasma (hyperimmune immunoglobulin) for COVID-19 management: An update
VP Chavda, R Bezbaruah, S Dolia, N Shah… - Process …, 2023 - Elsevier
The pandemic COVID-19 has spread widely throughout the globe and has been responsible
for millions of deaths worldwide. Recently, it has been identified that there is no specific and …
for millions of deaths worldwide. Recently, it has been identified that there is no specific and …
SARS-CoV-2 in immunocompromised individuals
S DeWolf, JC Laracy, MA Perales, M Kamboj… - Immunity, 2022 - cell.com
Immunocompromised individuals and particularly those with hematologic malignancies are
at increased risk for SARS-CoV-2-associated morbidity and mortality due to immunologic …
at increased risk for SARS-CoV-2-associated morbidity and mortality due to immunologic …
[HTML][HTML] The Fc-effector function of COVID-19 convalescent plasma contributes to SARS-CoV-2 treatment efficacy in mice
I Ullah, G Beaudoin-Bussières, K Symmes… - Cell Reports …, 2023 - cell.com
Summary COVID-19 convalescent plasmas (CCPs) are chosen for plasma therapy based on
neutralizing titers and anti-Spike immunoglobulin levels. However, CCP characteristics that …
neutralizing titers and anti-Spike immunoglobulin levels. However, CCP characteristics that …
Early treatment with monoclonal antibodies or convalescent plasma reduces mortality in non-vaccinated COVID-19 high-risk patients
L Thümmler, M Lindemann, PA Horn, V Lenz, M Konik… - Viruses, 2022 - mdpi.com
Vulnerable patients such as immunosuppressed or elderly patients are at high risk for a
severe course of COVID-19 upon SARS-CoV-2 infection. Immunotherapy with SARS-CoV-2 …
severe course of COVID-19 upon SARS-CoV-2 infection. Immunotherapy with SARS-CoV-2 …
Defining parameters that modulate susceptibility and protection to respiratory murine coronavirus MHV1 infection
EE Silva, SJ Moioffer, M Hassert, RR Berton… - The Journal of …, 2024 - journals.aai.org
Patients infected with SARS-CoV-2 experience variable disease susceptibility, and patients
with comorbidities such as sepsis are often hospitalized for COVID-19 complications …
with comorbidities such as sepsis are often hospitalized for COVID-19 complications …
Convalescent plasma for haematological patients with SARS-CoV-2 pneumonia and severe depletion of B-cell lymphocytes following anti-CD20 therapy: a single …
A Oliva, F Cancelli, A Brogi, A Curtolo… - New …, 2022 - iris.uniroma1.it
Convalescent plasma (CP) therapy might be effective in patients with haematological
malignanciesand B-cell depletion. We report a single-centre experience of COVID-19 …
malignanciesand B-cell depletion. We report a single-centre experience of COVID-19 …
Improved survival of lymphoma patients with COVID-19 in the modern treatment and vaccination era
A Della Pia, C Zhao, P Jandir, A Gupta, M Batistick… - Cancers, 2022 - mdpi.com
Simple Summary Patients with lymphoma are at greater risk of complications from COVID-19
infection. However, limited data exists on COVID-19-related outcomes in lymphoma patients …
infection. However, limited data exists on COVID-19-related outcomes in lymphoma patients …
Effectiveness of COVID-19 convalescent plasma (CCP) during the pandemic era: a literature review
UR Kandula, TS Tuji, DB Gudeta… - Journal of Blood …, 2023 - Taylor & Francis
Worldwide pandemic with coronavirus disease-2019 (COVID-19) was caused by severe
acute respiratory syndrome coronavirus-2 (SARS-CoV-2). As November 2, 2022, World …
acute respiratory syndrome coronavirus-2 (SARS-CoV-2). As November 2, 2022, World …
Prolonged Disease Course of COVID‐19 in a Patient with CTLA‐4 Haploinsufficiency
Patients with primary immunodeficiencies are especially vulnerable to developing severe
coronavirus disease 2019 (COVID‐19) after infection with the severe acute respiratory …
coronavirus disease 2019 (COVID‐19) after infection with the severe acute respiratory …